Viw Magazine

The Times


.

AIM Vaccine’s heavyweight single-product mRNA RSV Vaccine obtained the clinical trial approval

HONG KONG SAR - Media OutReach Newswire - 30 October 2024 - AIM Vaccine (06660.HK), the leader in Chinese mRNA vaccines, announced on 30th October that mRNA respiratory syncytial virus (RSV) vaccine developed by a controlled subsidiary of the Group , has been recently obtained from the National Medical Products Administration, which marks a new progress of the research and development of the vaccine.

Read more …

LifeStyle

What to Consider Before Choosing an Illuminated Mirror

An LED mirror combines a reflective surface with integrated illumination, making it useful in bathro...

How to Clear a Deceased Estate: A Gentle, Practical Guide for Sydney Families

Losing a loved one is hard enough. Then, often within weeks, families are faced with the task of s...

Science Tutoring Sydney: Building Strong Foundations in Science

Students and parents looking for science tutoring Sydney often want support that combines clear te...

Gym Solutions: How to Create a Practical Home Workout Space

Creating a workout area at home can make regular exercise more convenient, particularly for people...